Currently, several innovative diabetic agents are in the drug pipeline for NASH worldwide, including mTOT, GLP-1/GCGR agonist, GIP/GLP-1 agonist, and imeglimin. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.